| Literature DB >> 34679101 |
Hiroki Yabe1, Kenichi Kono2, Tomoya Yamaguchi3, Yumiko Ishikawa4, Yoshiko Yamaguchi4, Hisanori Azekura5.
Abstract
Previous reports have shown the benefits of intradialytic exercise to patients undergoing hemodialysis. However, most of those studies assessed the effects of exercise in middle-aged patients and little is known about advanced-age patients undergoing hemodialysis. Therefore, the present randomized controlled trial was performed to determine the effectiveness of exercise therapy in advanced-age patients undergoing hemodialysis. This non-blinded, randomized controlled parallel trial enrolled a total of 101 patients who were randomly assigned to intradialytic exercise (n = 51) or usual care (n = 50) groups. The training program included both resistance and aerobic exercises and was performed three times per week for 6 months. The aerobic exercise intensity was adjusted to a target Borg score of 13 for 20 minutes. Four types of resistance exercises were performed using elastic tubing, with three sets of 10 exercises performed at moderate intensity (13/20 on the Borg scale). The usual care group received standard care. Lower extremity muscle strength, Short Physical Performance Battery score, and 10-m walking speed were the outcomes and were evaluated before the hemodialysis session and after 6 months of training. There were statistically significant improvements in Short Physical Performance Battery score (effect size, 0.57; 95% confidence interval, 0.15‒1.95) in the exercise group relative to the control group. There were no statistically significant differences in lower extremity muscle strength or in the 10-m walking speed between the two groups. These findings suggest that 6 months of intradialytic training could improve physical function in older patients undergoing hemodialysis.Entities:
Mesh:
Year: 2021 PMID: 34679101 PMCID: PMC8535393 DOI: 10.1371/journal.pone.0257918
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow of participants.
Patient characteristics.
| All (n = 84) | Control (n = 40) | Exercise (n = 44) | p | |
|---|---|---|---|---|
| Age (year) | 78.8 ± 6.4 | 79 ± 6.7 | 78.7 ± 6.3 | 0.66 |
| Sex (men/women [n])) | 47/37 | 21/19 | 26/18 | 0.53 |
| Height (cm) | 155.3 ± 9.9 | 155.2 ± 10.2 | 155.4 ± 9.8 | 0.93 |
| Dry weight (kg) | 51.7 ± 9.4 | 51.3 ± 8.8 | 52.1 ± 10 | 0.71 |
| BMI (kg/m2) | 21.3 ± 2.7 | 21.3 ± 2.8 | 21.4 ± 2.6 | 0.82 |
| HD vintage (month) | 66.2 ± 70.9 | 70.9 ± 79.2 | 61.9 ± 63 | 0.75 |
| Disease (n [%]) | ||||
| Nephrosclerosis | 35 (41.7) | 16 (40) | 19 (43.2) | 0.76 |
| Diabetes | 21 (25) | 8 (20) | 13 (29.5) | 0.31 |
| Chronic glomerulonephritis | 19 (22.6) | 11 (27.5) | 8 (18.2) | 0.31 |
| Others | 9 (10.7) | 5 (12.5) | 4 (9.1) | 0.61 |
| Medication (n [%]) | ||||
| Ca antagonist | 29 (34.5) | 10 (25) | 19 (43.2) | 0.08 |
| ARB | 25 (29.8) | 9 (22.5) | 16 (36.4) | 0.16 |
| ACE inhibitor | 0 (0) | 0 (0) | 0 (0) | - |
| β blocker | 14 (16.7) | 4 (10) | 10 (22.7) | 0.12 |
| Laboratory data | ||||
| Alb (g/dL) | 3.7 ± 0.3 | 3.7 ± 0.3 | 3.8 ± 0.3 | 0.28 |
| GNRI | 96.4 ± 7.1 | 95.8 ± 6.7 | 96.9 ± 7.6 | 0.50 |
| P (mg/dL) | 5.4 ± 1.5 | 5.4 ± 1.6 | 5.3 ± 1.3 | 0.67 |
| Ca (mg/dL) | 8.5 ± 0.8 | 8.6 ± 0.8 | 8.5 ± 0.8 | 0.78 |
| K (mEq/L) | 4.6 ± 0.7 | 4.7 ± 0.6 | 4.5 ± 0.7 | 0.10 |
| nPCR | 0.9 ± 0.2 | 0.9 ± 0.2 | 0.9 ± 0.2 | 0.91 |
| Kt/V | 1.5 ± 0.3 | 1.5 ± 0.3 | 1.5 ± 0.3 | 0.64 |
| Hb (g/dL) | 10.8 ± 0.9 | 10.7 ± 0.9 | 10.9 ± 1 | 0.33 |
| CRP (mg/dL) | 0.5 ± 1.3 | 0.8 ± 1.8 | 0.3 ± 0.4 | 0.10 |
| Vascular acsess (n[%]) | ||||
| AVF | 73(86.9) | 33(82.5) | 40(90.9) | 0.34 |
| AVG | 11(13.1) | 7(17.5) | 4(9.1) |
BMI: body mass index; HD: hemodialysis; ARB: angiotensin receptor blocker; ACE: angiotensin converting enzyme; Alb: serum albumin; GNRI: geriatric nutritional risk index; P: serum phosphorus; Ca: serum calcium; K: serum potassium; nPCR: normalized protein catabolic rate; Hb: hemoglobin; CRP: C‒reactive protein; AVF, arteriovenous fistula; AVG, arteriovenous graft.
Mean ± standard deviation.
Comparison between exercise and control groups before and after an intervention.
| Control | Exercise | Adjusted mean difference (95% CI) | Effect size | p | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| pre | post | p | Δ | pre | post | p | Δ | ||||
| LES | 17.4 ± 7.8 | 15.2 ± 6.8 | 0.80 | 0.3 ± 4.1 | 16.7 ± 8.9 | 16.7 ± 8.9 | 0.69 | -0.6 ± 5.6 | 0.94 (-1.22 to 3.09) | 0.18 | 0.64 |
| 10-m walking speed | 1.1 ± 0.5 | 1.1 ± 0.4 | 0.89 | 0 ± 0.4 | 1.1 ± 0.3 | 1.1 ± 0.3 | 0.78 | 0 ± 0.2 | -0.02 (-0.15 to 0.12) | 0.00 | 0.54 |
| SPPB | 10 (7.0‒12.0) | 9 (7.0‒11.0) | 0.12 | 0 (-1.5 to 0) | 10 (7.0‒11.3) | 12 (8.6‒12.0) | 0.04 | 1 (0‒2.0) | 1.05 (0.15‒1.95) | 0.57 | 0.01 |
Values are expressed as mean ± SD or median (interquartile range) according to normality by Shapiro-Wilk test. CI, confidence interval; LES, lower extremity muscle strength; SPPB, Short Physical Performance Battery; Δ, 6-month value—baseline value.
†: Significant difference between the pre and post intervention by Wilcoxon signed-rank sum test (p < 0.05).
*: Significant difference between the control group by ANCOVA (p < 0.05).